“OM Investors Can Take Initiative in Outset Medical, Inc. Securities Fraud Case”

Avatar photo

Investors Take Action: Class Action Lawsuit Filed Against Outset Medical

LOS ANGELES, Oct. 11, 2024 /PRNewswire/ — Glancy Prongay & Murray LLP (“GPM”) announces that investors who suffered significant losses can now lead a securities fraud class action lawsuit against Outset Medical, Inc. (“Outset Medical” or the “Company”) OM.

Glancy Prongay & Murray LLP (PRNewsfoto/Glancy Prongay & Murray LLP)

Class Period: August 1, 2022August 7, 2024
Lead Plaintiff Deadline: October 28, 2024

Those interested in serving as lead plaintiff in the Outset Medical lawsuit can provide their contact information at www.glancylaw.com/cases/Outset-Medical-Inc-1/. For more information about your rights, you may also reach out to Charles H. Linehan from GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected].

The filed complaint claims that during the Class Period, Defendants failed to inform investors of critical issues, such as: (1) Tablo products were marketed for continuous renal replacement therapy despite lacking FDA approval; (2) Outset Medical might have to submit a new 510(k) application for the Tablo products; (3) there was a significant chance the Company would halt Tablo product sales while awaiting FDA approvals; (4) Outset Medical did not have the appropriate sales team to support Tablo sales growth; (5) these factors would negatively affect the company’s revenue increase; and (6) Defendants’ optimistic statements about the Company’s business were materially misleading.

Stay updated by following GPM on LinkedIn, Twitter, or Facebook.

If you wish to be part of this class action, no immediate action is needed. You may choose to retain your own counsel or simply remain an absent member of the class. For further details or if you have any questions about this lawsuit, please contact Charles Linehan, Esquire of GPM at 1925 Century Park East, Suite 2100, Los Angeles, California 90067, by calling 310-201-9150, Toll-Free at 888-773-9224, or via email to [email protected]. If emailing, please include your mailing address, phone number, and the number of shares purchased.

This press release may be considered Attorney Advertising in certain jurisdictions as per applicable laws and ethical rules.

Contacts

Glancy Prongay & Murray LLP, Los Angeles
Charles Linehan, 310-201-9150 or 888-773-9224
[email protected]
www.glancylaw.com

Cision View original content to download multimedia: Link to original content

SOURCE Glancy Prongay & Murray LLP

Market News and Data brought to you by Benzinga APIs

The free Daily Market Overview 250k traders and investors are reading

Read Now